|
EORTC AISBL / IVZW |
|
|
EORTC AISBL / IVZW |
Open studies are marked with a purple background, closed studies have a grey background, studies to be opened have a white background
| 62006 | Exatecan as second line treatment in advanced adult soft tissue sarcoma: A phase II study of the EORTC Soft Tissue and Bone sarcoma Group. (Study only open for patients with Leiomyosarcoma) |
| 62002 | Phase I study to determine the safety of Caelyx (Doxorubicin HCI, pegylated liposomal) in combination with Ifosfamide in previously untreated adult patients with advanced and/or metastatic soft tissues sarcomas. |
| 62001 | Dose finding and phase II study of STI 571 in advanced soft tissue sarcoma. |
| 62982 | Phase II study on ET-743 in advanced soft tissue sarcomas of the adult. |
| 62972 | Phase II Study on Gemcitabine in advanced soft tissue sarcomas of the adult |
| 62971 | Randomized phase III trial of two investigational schedules of Ifosfamide versus standard dose Doxorubicin in patients with advanced or metastatic soft tissue sarcoma. |
| 62962 | Phase II Study of Caelyx (Doxorubicin HCl, pegylated liposomal) or Doxorubicin in previously untreated adult patients with advanced and/or metastatic soft tissue sarcomas. |
| 62953 | Phase II study on HD Ifosfamide in advanced soft tissue sarcomas of the adult |
| 62922 | Phase II trial of temozolomide in adult patients with advanced soft tissue sarcoma |
| 62941 | Randomized multicenter phase III trial comparing Docetaxel to Doxorubicin in previously untreated patients with advanced and/or metastatic soft tissue sarcoma |
| 62932 | Phase II study of daily oral vepeside (etoposide VP16-213) as second line treatment in advanced soft tissue sarcomas |
| 62921 | A phase II trial with taxotere (RP56976) in advanced soft tissue sarcomas of the adult |
| 62903 | Randomized phase III study comparing conventional dose Doxorubicin plus Ifosfamide vs high dose Doxorubicin plus Ifosfamide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in the treatment of advanced soft tissue sarcomas in adults |
| 04914 | Etude de phase II d'un nouveau derive du platine, le lobaplatine (SAR 540), dans les sarcomes avanc‚s des tissus mous de l'adulte |
| 62911 | Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/PE) in advanced soft tissue sarcoma of the adult |
| 62901 | Randomized phase II-III study comparing adriamycin versus two schedules of high dose Epirubicin in advanced soft tissue sarcoma |
| 04891 | Essais cliniques phase II d'une nouvelle nitrosourée: la Cystémustine dans les poumons, les adénocarcinomes colo-rectaux, les gliomes, les mélanomes, les reins, les sarcomes des parties molles et les tumeurs de la tête et du cou. |
| 62883 | Phase II clinical study of the use of granulocyte-macrophage colony-stimulating factor (GM-CSF) with chemotherapy (adriamycin andifosfamide) in the treatment of advanced soft tissue sarcomas in adults |
| 62881 | PHASE II STUDY OF ACNU IN METASTATIC SOFT TISSUE SARCOMA |
| 04861 | Etude clinique phase II 4' -0-tetrahydropyranyl adriamycine (THP-ADM-1609 RB) |
| 62851 | Phase III trial of first line chemotherapy (adriamycin vs adriamycin + ifosfamide vs cyvadic) in advanced soft tissue sarcoma |
| 62771 | Randomized trial for Adjuvant Chemotherapy in soft tissue sarcoma |
| 62043 | Phase II study of GW786034 in patients with relapsed or refractory soft tissue sarcoma |
| 62005 | Phase III randomised, intergroup, international trial assessing the clinical activity of STI-571 at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) expressing the KIT receptor tyrosine kinase (CD117) |
| 62961 | Randomized study comparing neoadjuvant chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) combined with regional hyperthermia (RHT) Vs neoadjuvant chemotherapy alone in the treatment of high-risk soft tissue sarcomas in adults. An Intergroup study with the European Society for hyperthermic oncology. |
| 90061 | Multicenter parallel phase II trial of BI 2536 administrered as one hour i.v. infusion every 3 weeks in defined cohorts of patients with various solid tumors. A new drug screening program of the EORTC Network of Core Institutions (NOCI) |
| 62061 | Randomized phase II study of brostallicin (PNU-166196A) versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma |
| 62024 | Intermediate and high risk localized,completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor : a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no further therapy after complete surgery. |
| 62027 | Phase 2 study of Glivec (Imatinib) in locally advanced and/or metastatic soft tissue sarcomas expressing the t(17;22) (q22;q13) translocation resulting in a COL1A1/PDGF- beta fusion protein i.e. DermatoFibroSarcoma Protuberans (DFSP) and Giant Cell Fibroblastoma (GCF) |
| 62931 | Randomized phase III trial of adjuvant chemotherapy with high-dose doxorubicin, ifosfamide and lenograstim in high grade soft tissue sarcoma. |
| 62022 | Phase 2 study of Iressa (ZD 1839) in locally advanced and/or metastatic synovial sarcoma expressing HER1/EGFRI. |
| 62991 | Phase II pilot study of moderate dose radiotherapy for inoperable aggressive fibromatosis |
| 62933 | Metastasectomy and chemotherapy for lung metastases from soft tissue sarcoma. A randomized phase III study (an Intergroup Study with the Scandinavian Sarcoma Group) |
| 62091 | A phase IIb/III multicenter study comparing the efficacy of Trabectedin administered as a 3-hour or 24 hour infusion to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma |
| 62063 | A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate. |
| 62072 | A randomized double blind phase III trial of Pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy. |
| 62052 | Phase II study of E7389 administered as an IV infusion on day 1 and 8 every 3 weeks in pretreated patients with advanced and/or metastatic soft tissue sarcoma |
| 62012 | Randomised trial of single agent doxorubicin versus doxorubicin plus ifosfamide in the first line treatment of advanced or metastatic soft tissue sarcoma |
| 62993 | A phase II study to evaluate the role of weekly Cisplatin with oral Etoposide in Ewing's sarcoma and primitive neuroectodermal tumour (PNET) with metastasis outside the lung and the pleura. |
| 62951 | Phase II study on Tomudex in advanced soft tissue sacromas of the adult |
| 62912 | Randomized phase II study comparing two different Ifosfamide dose regimens |
| 62902 | PHASE II STUDY OF DAILY ORAL MILTEFOSINE (HEXADECYLPHOSPHOCHOLINE) IN ADVANCED SOFT TISSUE SARCOMAS OF THE ADULT. |
| 62874 | Randomized phase II study of neoadjuvant chemotherapy in soft tissue sarcomas in adults |
| 62871 | Phase II Chemotherapy with m-Azidopyrimethamine in Adults with Metastatic Soft Tissue Sarcoma (Summary Last Modified 05/88) |
| 62863 | Phase II study of Mitozolomide in metastatic soft tissue sarcoma |
| 62861 | Phase II Chemotherapy with Methylene Dimethane Sulphonate in Patients with Soft Tissue Sarcomas |